PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives

Veterinary and Comparative Oncology

Volumn 8, Issue 3, 2010, Pages 163-187

  Lawrence, J ^a   Rohren, E ^b   Provenzale, J ^c,d  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Functional imaging; Oncology; PET CT; Radiopharmaceutical; Response assessment

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANIMAL; ANIMAL DISEASE; CANCER STAGING; CAT; CAT DISEASE; DOG; DOG DISEASE; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; HUMAN; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 77955248175     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00218.x     Document Type: Review

References (150)

1. West J, Fitzpatrick JM, Wang MY, Dawant BM, Maurer CR, Kessler RM, Maciunas RJ, Barillot C, Lemoine D, Collignon A, Maes F, Suetens P, Vandermeulen D, van den Elsen PA, Napel S, Sumanaweera TS, Harkness B, Hemler PF, Hill DL, Hawkes DJ, Studholme C, Maintz JBA, Viergever MA, Malandain G, Pennec X, Noz ME, Maguire GQ, Pollack M, Pelizzari CA, Robb RA, Hanson D, Woods RP. Comparison and evaluation of retrospective intermodality brain image registration techniques. J Comput Assist Tomogr 1997, 21:554-566.
2. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007, 242:360-385.
3. Jager PL, Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, de Vries EG. Molecular imaging: what can be used today. Cancer Imaging 2005, 5:S29-S32.
4. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991, 32:623-648.
5. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001, 41(Suppl):96S-103S.
6. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007, 13:3460-3469.
7. Greven KM, Williams DW, Keyes JW, McGuirt WF, Watson NE, Randall ME, Raben M, Geisinger KR, Cappellari JO. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994, 74:1355-1359.
8. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998, 25:1255-1260.
9. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, Wahl RL. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996, 200:135-141.
10. Schiepers C, Penninckx F, De vadder N, Merckx E, Mortelmans L, Bormans G, Marchal G, Filez L, Aerts R. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995, 21:517-522.
11. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, Fleshman JW, Read TE, Philpott GW, Kodner IJ. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997, 4:613-620.
12. Schoder H, Grimm J, Larson SM. Molecular imaging. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology 2008, 746-766. DeVita VT, Lawrence TS, Rosenberg SA. In:, 8th edn, eds., Philadelphia, Lippincott Williams & Wilkins
13. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000, 41:1369-1379.
14. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002, 75:S24-S30.
15. Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, Nutt R, Meltzer CC, Villemagne V, Townsend D. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000, 25:905-910.
16. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend D. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 2000, 3:223-230.
17. Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med 2008, 38:152-166.
18. Pan T, Mawlawi O. PET/CT in radiation oncology. Med Phys 2008, 35:4955-4966.
19. Mawlawi O, Townsend D. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med 2009, 36:S15-S29.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50:122S-150S.
21. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066. National Cancer Institute
22. Boellard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EF, Pruim J. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 2008, 35:2320-2333.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
24. Beyer T, Pichler B. A decade of combined imaging: from a PET attached to a CT to a PET inside an MR. Eur J Nucl Med Mol Imaging 2009, 36:S1-S2.
25. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy- D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004, 22:4357-4368.
26. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature based evidence as of September 2006. J Nucl Med 2007, 48(Suppl):78S-88S.
27. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008, 26:2155-2161.
28. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB. 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound 2009, 50:214-223.
29. LeBlank AK, Daniel GB. Advanced imaging for veterinary cancer patients. Vet Clin North Am Small Anim Pract 2007, 37:1059-1077.
30. Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM. Use of 3′-deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Vet Radiol Ultrasound 2009, 50:660-668.
31. Ballegeer EA, Forrest LJ, Jeraj R, Mackie TR, Nickles J. PET/CT following intensity-modulated radiation therapy for primary lung tumor in a dog. Vet Radiol Ultrasound 2006, 47:228-233.
32. Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med 1994, 35:1506-1513.
33. Bassett CM, Daniel GB, Legendre AM, Bochsler PN, Smith GT. Characterization of uptake of 2-deoxy-2-[18F]fluoro-D-glucose by fungal-associated inflammation: the standardized uptake value is greater for lesions of blastomycosis than for lymphoma in dogs with naturally occurring disease. Mol Imaging Biol 2002, 4:201-207.
34. Bruehlmeier M, Kaser-Hotz B, Achermann R, Bley CR, Wergin M, Schubiger PA, Ametamey SM. Measurement of tumor hypoxia in spontaneous canine sarcomas. Vet Radiol Ultrasound 2005, 46:348-354.
35. Larson SM, Weiden PL, Grunbaum Z, Kaplan HG, Rasey JS, Graham MM, Sale GE, Harp GD, Williams DL. Positron imaging feasibility studies. II. Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms: concise communication. J Nucl Med 1981, 22:869-874.
36. Hutton BF, Braun M. Software for image registration: algorithms, accuracy, efficacy. Semin Nucl Med 2003, 33:180-192.
37. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993, 34:1190-1197.
38. Reinartz P, Wieres FJ, Schneider W, Schur A, Buell U. Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging 2004, 31:1456-1461.
39. Phelps M. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000, 87:9226-9233.
40. Townsend DW. Physical principles and technology of clinical PET imaging. Ann Acad Med Singapore 2004, 33:133-145.
41. Zanzonico P. Positron emission tomography: a review of basic principles, scanner design and performance, and current systems. Semin Nucl Med 2004, 34:56-69.
42. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT Scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007, 48:471-480.
43. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW. Impact of time-of-flight on PET tumor detection. J Nucl Med 2009, 50:1315-1323.
44. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging 2006, 21:99-110.
45. Tsukamoto E, Ochi S. PET/CT today: system and its impact on cancer diagnosis. Ann Nucl Med 2006, 20:255-267.
46. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004, 45(Suppl):4S-14S.
47. Sachelarie I, Kerr K, Ghesani M, Blum RH. Integrated PET-CT: evidence based review of oncology indications. Oncology 2005, 19:481-490.
48. Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, Chu SK. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005, 46:283-291.
49. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 2005, 46:1481-1487.
50. Cherry SR. The 2006 Henry N Wagner lecture: of mice and men (and positrons)-advances in PET/CT technology. J Nucl Med 2006, 47:1735-1745.
51. Stickel JR, Cherry SR. High resolution PET detector design: modeling components of intrinsic spatial resolution. Phys Med Biol 2005, 50:179-195.
52. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac H. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 2004, 45:1734-1742.
53. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 2007, 48(Suppl):36S-44S.
54. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004, 45:1431-1434.
55. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. Am J Roentgenol 2009, 192:956-962.
56. Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 2009, 115:3548-3554.
57. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2009, 75(Supp1):S357-S358.
58. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007, 15:1738-1744.
59. Sato M, Okumura T, Kaito K, Kiyoshima M, Asato Y, Uchiumi K, Iijima H, Hashimoto I, Kaburagi T, Amemiya R. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer. Ann Nucl Med 2009, 23:49-57.
60. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004, 45:1519-1527.
61. 2009, http://interactive.snm.org/index.cfm?PageID=8813, Society of Nuclear Medicine Clinical Trials Network, [accessed 22 March 2009].
62. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007, 8:822-830.
63. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007, 13:3470-3481.
64. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28:897-916.
65. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005, 32:663-671.
66. Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology: part 1. Expert Rev Anticancer Ther 2005, 5:1079-1094.
67. Keyes JW. SUV: standard uptake value or silly useless value? J Nucl med 1995, 36:1836-1839.
68. Warburg O. The Metabolism of Tumors 1931, New York, Richard Smith
69. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004, 4:891-899.
70. Linden HM, Krohn KA, Livingston RB, Mankoff DA. Monitoring targeted therapy: is fluorodeoxyglucose uptake a marker of early response? Clin Cancer Res 2006, 12:5608-5610.
71. Mathapala SP, Rempel A, Pederson PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997, 29:339-343.
72. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 1997, 29:355-364.
73. Cook GJ. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging 2007, 51:235-243.
74. Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, Corone C, Tainturier C, Pecking AP. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol 2005, 185:495-500.
75. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11:2785-2808.
76. LeBlanc AK, Jakoby B, Townsend DW, Daniel GB. Thoracic and abdominal uptake of 2-deox-2-[18F]fluoro-D-glucose (18FDG) with positron emission tomography in the normal dog. Vet Radiol Ultrasound 2008, 49:182-188.
77. LeBlanc AK, Wall JS, Morandi F, Kennel SJ, Stuckey A, Jakoby B, Townsend DW, Daniel GB. Normal thoracic and abdominal distribution of 2-deox-2-[18F]fluoro-D-glucose (18FDG) in adult cats. Vet Radiol Ultrasound 2009, 50:436-441.
78. Kirk CA, Debrakeleer J, Armstrong PJ, Hand MS, Thatcher CD, Remillard RL, Roudebush P. Normal cats. Small Animal Clinical Nutrition 2000, 291-347. In:, 4th edn, eds., Topeka, KS, Mark Morris Institute
79. Ghambir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42(Suppl):1S-93S.
80. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002, 225:575-581.
81. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003, 44:1200-1209.
82. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507.
83. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94:429-433.
84. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997, 203:795-800.
85. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998, 206:475-481.
86. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin's lymphoma. Ann Oncol 2005, 16:1514-1523.
87. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003, 14:123-130.
88. Romer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998, 91:4464-4471.
89. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13:1356-1363.
90. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571-578.
91. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005, 23:4652-4661.
92. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004, 6:411-416.
93. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004, 231:305-332.
94. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009, 50(Suppl):97S-105S.
95. Van den Abbeele AD, Badawi BD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(Suppl):S60-S65.
96. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib Mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020.
97. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001, 19:2797-2803.
98. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of 'metabolic flare' to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999, 26:51-56.
99. Cleaver JE. Thymidine metabolism and cell kinetics. Frontiers Biol 1967, 6:43-100.
100. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005, 43:153-167.
101. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 4:1334-1336.
102. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, Mattfeldt T, Tepsic D, Bunjes D, Mottaghy FM, Krause BJ, Neumaier B, Döhner H, Möller P, Reske SN. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006, 66:11055-11061.
103. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithauser F, Wawra E, Munzert G, Reske SN. 3′-Deoxy-3′[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003, 63:2681-2687.
104. Barthel H, Cleij M, Collingridge O, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO. 3′-Deoxy-3′[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003, 63:3791-3798.
105. Been LB, Suurmeijer AJH, Cobben DC, Jager PL, Hoekstra JH, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med 2004, 31:1659-1672.
106. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002, 53:89-112.
107. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A-549 carcinoma cells. J Nucl Med 2002, 42:1210-1217.
108. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995, 35:69-89.
109. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994, 30:391-398.
110. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell boil 1991, 11:2538-2546.
111. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002, 29:1462-1469.
112. Francis DL, Loizidou M, Visvikis D, DeVos S, Luthra SK, Taylor I. Monitoring 5-fluorouracil chemotherapy response in colorectal cancer using positron emission tomography. Eur J Surg Oncol 2003, 29:789.
113. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001, 42:721-725.
114. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, Kanaji N, Asakura M, Ohkawa M. Comparison of 18F-FLT and 18F-FDG uptake on PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008, 35:236-245.
115. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: A comparative analysis. J Nucl Med 2007, 48:1945-1950.
116. Pio BS, Park CK, Satyamurthy N, Czernin J, Phelps ME, Silverman DH. PET with fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy. J Nucl Med 2003, 44(Suppl):246. p.
117. Chen W, Clughsey T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005, 46:945-952.
118. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, Yin Y, Fu Z, Mu D, Zhang B, He W, Huo Z, Liu X, Kong L, Zhao S, Sun X. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2009, 76:1235-1241.
119. Padhani AR. Where are we with imaging oxygenation in human tumours? Cancer Imaging 2005, 28:128-130.
120. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygentation of human tumours. Eur Radiol 2007, 17:861-872.
121. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989, 17:985-991.
122. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
123. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch JM. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
124. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42:655-661.
125. Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, Simpson E, Parkey RW, Sun X, Ox OK. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. J Nucl Med 2009, 50:1332-1339.
126. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
127. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51:1641-1648.
128. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging 2009, 53:193-200.
129. Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, Gabelmann A, Hetzel J, Hombach V, Schirrmeister H. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003, 18:2206-2214.
130. Thrall JH. Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev Clin Radiol Nucl Med 1976, 8:1-31.
131. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med 1972, 2:31-37.
132. Grant FD, Fahey FH, Packard AB, Davis AT, Alavi A, Treves ST. Skeletal PET with 18F-Floride: applying new technology to an old tracer. J Nucl Med 2008, 49:68-78.
133. Hockley BG, Scott PJH. An automated method for preparation of [18F] sodium floride for injection, USP to address the technetium-99m isotope shortage. Appl Radiat Isot 2010, 68:117-119.
134. Costeas A, Woodard HQ, Laughlin JS. Depletion of 18F from blood flowing through bone. J Nucl Med 1970, 11:43-45.
135. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 2001, 31:28-49.
136. Hyldstrup L, McNair P, Ring P, Henriksen O. Studies on diphosphonate kinetics. Part I: evaluation of plasma elimination curves during 24 h. Eur J Nucl Med 1987, 12:581-584.
137. Park-Holohan SJ, Blake GM, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun 2001, 22:1037-1044.
138. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, Schiepers CW, Huang SC, Satyamurthy N, Barrio JR, Phelps ME. Whole body skeletal imaging with [18F]fluoride ion with PET. J Comput Assist Tomogr 1993, 17:34-41.
139. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN. Sensitivity in detecting osseious lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.
140. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999, 17:2381-2389.
141. Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med 2009, 36:1807-1812.
142. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006, 36:73-92.
143. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998, 209:253-258.
144. CMS issues proposed decision memo for PET (NaF-18) to identify bone metastasis of cancer (CAG 00065R1) (CAG-00065R). http://interactive.snm.org/index.cfm?PageID=9307, [, accessed, 22 March 2009].
145. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36:1766-1774.
146. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H. Tumor localization of 16-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45:366-373.
147. Gonzalez Trotter DE, Manjeshwar RM, Doss M, Shaller C, Robinson MK, Tandon R, Adams GP, Adler LP. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004, 45:1237-1244.
148. Koglin N, Anton M, Hauser A, Saur D, Algul H, Schmid R, Gansbacher B, Schwaiger M, Wester HJ. CXCR4 chemokine receptor SPECT/PET imaging with radiolabeled CPCR4: a promising approach for imaging metastatic processes. J Nucl Med 2006, 47:505. p.
149. Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, Lee Stone K, Martinez TD, Miller KD, Sledge GW, Hutchins GD. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C] methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002, 29:761-770.
150. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009, 36(Suppl):S3-S9.